-+ 0.00%
-+ 0.00%
-+ 0.00%
HLB to Absorb HLB Life Science in Share-Swap Merger
Share
Listen to the news
HLB to Absorb HLB Life Science in Share-Swap Merger
  • HLB will absorb HLB Life Science in a stock-based merger scheduled to take effect July 1, 2027.
  • HLB Life Science shareholders will receive 0.0857532 shares in the surviving company for each share held.
  • The transaction will involve issuing 8,674,057 common shares, equivalent to 6.51% of the surviving company's current outstanding shares.
  • The merger aims to consolidate rights and revenue streams for cancer drug rivoceranib while simplifying the group structure.
  • Completion remains subject to HLB Life Science shareholder approval and competition clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLB Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261119000398), on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending